Danaher - DHR Enterprise Value-to-Revenue Multiple

danaher.com (DHR) - corporate logo

Customer dependence on consumables creates a risk of pricing pressure, yet the EV/Sales ratio of Danaher Corp. demonstrates resilience. The 7115.26 level serves as the current support level. The asset's stability is driven by the aggressive acquisition of niche players and a flawless reputation within the scientific community, guaranteeing the dominance of Danaher Corp. in the high-tech medical instrumentation market.

DHR: Danaher Corporation Company Value to Revenue 11/23/2025 - 11/20/2026

Danaher Corp. - analytical breakdowns and key metrics (DHR)

- market value and analyst target forecast:
Fundamental company valuation:DHR - danaher.com
Original product of Danaher Corporation Inc.

Danaher Corp. scales its business through acquisitions and lean manufacturing, creating a resilient platform for biomedical research. The EV/Sales metric assesses the total enterprise value (market capitalization plus net debt) relative to annual revenue, eliminating distortions from the financing structure. A stable enterprise value-to-sales ratio confirms market confidence in the effectiveness of the growth strategy and the security of the issuer's cash flows.

Competitor analysis

ISRG - EV/Sales Multiple|BDX: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple STERIS PLC (STE)|Enterprise Value-to-Revenue Ratio West Pharmaceutical Services|Company Value to Revenue Ratio BAX (Baxter International)|Enterprise Value-to-Revenue Ratio Masimo (MASI)|Stevanato Group - Company Value to Revenue Ratio|Enterprise Value-to-Revenue Ratio Teleflex Inc. TFX|Enterprise Value-to-Revenue Coefficient MMSI (Merit Medical Systems, Inc.)|NVST - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio ICU Medical Corp ICUI|XRAY: EV/Sales Multiple|LMAT (LeMaitre Vascular, Inc.) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue ATRC|STAA (STAAR Surgical) - Enterprise Value-to-Revenue Coefficient|Enterprise Value-to-Revenue Ratio ChromaDex (NAGE)|Company Value to Revenue ZimVie Inc. ZIMV|EV/Sales Multiple ANGO (angiodynamics.com)|EV/Sales Multiple cerus.com CERS|teknova.com - EV/Sales Multiple|Enterprise Value-to-Sales Ratio Monogram Technologies Inc. (MGRM)|Sharps Technology, Inc. (STSS) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple InfuSystem Inc (INFU)|UTMD (Utah Medical Products Inc.) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple KORU Medical Systems KRMD|Enterprise Value-to-Revenue Ratio Nyxoah SA (NYXH)|Enterprise Value-to-Revenue Coefficient MBOT|EV/Sales Multiple PDEX (Pro-Dex Inc.)|Enterprise Value-to-Revenue Coefficient ZTEK (Zentek Limited)|elutia.com - EV/Sales Multiple|Business Value to Revenue MLSS (milestonescientific.com)|NXGL (NEXGEL Inc.) - Company Value to Revenue|Retractable Technologies - Business Value to Revenue|Enterprise Value-to-Revenue Ratio harvardbioscience.com|Femasys Corp (FEMY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple MHUA|Predictive Oncology Inc. - Company Value to Revenue Ratio|EV/Sales Multiple CJMB (Callan JMB Inc)|EV/Sales Multiple Atrion Corp ATRI|NeuroMetrix Corporation - EV/Sales Multiple